Cargando…
Pharmacologicaltreatment of COVID-19: lights and shadows
At the end of December 2019, a novel coronavirus, the severe acute respiratory syndrome coronavirus 2, caused an outbreak of pneumonia spreading from Wuhan, Hubei province, to the whole country of China and then the entire world, forcing the World Health Organization to make the assessment that the...
Autores principales: | Menzella, Francesco, Biava, Mirella, Barbieri, Chiara, Livrieri, Francesco, Facciolongo, Nicola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241590/ https://www.ncbi.nlm.nih.gov/pubmed/32499832 http://dx.doi.org/10.7573/dic.2020-4-6 |
Ejemplares similares
-
COVID-19: general overview, pharmacological options and ventilatory support strategies
por: Menzella, Francesco, et al.
Publicado: (2020) -
Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?
por: Menzella, Francesco, et al.
Publicado: (2019) -
Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights
por: Menzella, Francesco, et al.
Publicado: (2020) -
May 2020: Is It Always COVID-19 No Matter What?
por: Livrieri, Francesco, et al.
Publicado: (2020) -
Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021)